Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis
نویسندگان
چکیده
منابع مشابه
Certolizumab pegol for the treatment of rheumatoid arthritis.
INTRODUCTION Improved understanding of the pathogenesis of rheumatoid arthritis (RA), and subsequent development of targeted therapies, have greatly advanced the management of this chronic inflammatory disease. The aim of treatment is a state of clinical remission. Certolizumab pegol (CZP) is a novel pegylated TNF alpha inhibitor (TNFi) therapy and is the focus of this review. AREAS COVERED C...
متن کاملCertolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of certolizumab pegol (CZP) for adults with active rheumatoid arthritis (RA) that have not responded adequately to treatment with conventional disease modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX), in accordance with the licensed indication, based...
متن کاملTwo Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
OBJECTIVE To investigate clinical efficacy and safety of 2 certolizumab pegol (CZP) maintenance dosing regimens plus methotrexate (MTX) in active rheumatoid arthritis (RA) patients achieving the American College of Rheumatology 20% improvement criteria (ACR20) after the CZP 200 mg every 2 weeks open-label run-in period. METHODS DOSEFLEX (dosing flexibility) was a double-blind, placebo-control...
متن کاملCertolizumab pegol for rheumatoid arthritis: effective in combination with methotrexate or as monotherapy
Rheumatoid arthritis (RA) is estimated to affect 5 million people worldwide [1] with 0.3–1% of the population in industrialized countries suffering from RA [2]. The development of RA is associated with increasing age and female gender, with the prevalence among women being approximately two-times greater than in men [3]. Although the etiology of RA remains unclear, the inflammation and joint da...
متن کامل99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study
BACKGROUND Biologicals directed against tumour necrosis factor (TNF) have proven their efficacy in the treatment of spondyloarthritis and rheumatoid arthritis. We present a radiolabelling method for certolizumab pegol (CZP), a commercially available humanized Fab'-fragment directed against TNF. A biodistribution and dosimetry study was conducted. Tc-S-HYNIC CZP was synthesized. The in vitro TNF...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Opinion on Drug Delivery
سال: 2016
ISSN: 1742-5247,1744-7593
DOI: 10.1080/17425247.2016.1256283